BRAK and APRIL as novel biomarkers for ovarian tumors

Heeyon Kim; Bo Hee Won; Jae Il Choi; Inha Lee; Jae Hoon Lee; Joo Hyun Park; Young Sik Choi; Jae Hoon Kim; Si Hyun Cho; Jong Baeck Lim; Byung Seok Lee

doi:10.2217/bmm-2021-1014

BRAK and APRIL as novel biomarkers for ovarian tumors

Heeyon Kim, Bo Hee Won, Jae Il Choi, Inha Lee, Jae Hoon Lee, Joo Hyun Park, Young Sik Choi, Jae Hoon Kim, Si Hyun Cho, Jong Baeck Lim, Byung Seok Lee

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

Abstract

Aims: To evaluate BRAK and APRIL in serum samples from healthy patients and an ovarian tumor group and analyze their effective value as biomarkers. Materials and methods: BRAK and APRIL were measured in 197 serum samples including 34 healthy controls, 48 patients with benign ovarian cysts and 115 patients with ovarian cancer, and the best statistical cut-off values were calculated. Then, the sensitivity, specificity, accuracy, positive predictive value and negative predictive value for selected cut-off points were assessed. Results: The healthy control group had statistically significant higher BRAK and lower APRIL than the ovarian tumor group. BRAK was excellent for differentiating healthy patients from patients with ovarian tumors, showing area under the receiver operating characteristic curve 0.983, 98.16% sensitivity and 100% specificity. When BRAK was combined with APRIL and CA-125, it also played a role in distinguishing benign cysts from malignancies with area under the curve 0.864, 81.74% sensitivity and 79.17% specificity. Conclusions: BRAK and APRIL are good candidates for ovarian tumor biomarkers.

Original language	English
Pages (from-to)	717-729
Number of pages	13
Journal	Biomarkers in Medicine
Volume	16
Issue number	9
DOIs	https://doi.org/10.2217/bmm-2021-1014
Publication status	Published - 2022 Jun

Bibliographical note

Funding Information:
This research was supported by a grant from the Korea Health Technology RandD Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant number HI18C2047) and supported by the National Research Foundation of Korea grant funded by the Korea government (2017R1A2B2011728).

Funding Information:
This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI18C2047) and supported by the National Research Foundation of Korea grant funded by the Korea government (2017R1A2B2011728). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Funding Information:
Human serums were provided by the Korea Gynecologic Cancer Bank through the Bio & Medical Technology Development Program of the Ministry of Education, Science and Technology, Korea (NRF-2017M3A9B8069610).

Publisher Copyright:
© 2022 Future Medicine Ltd.

All Science Journal Classification (ASJC) codes

Drug Discovery
Clinical Biochemistry
Biochemistry, medical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/bmm-2021-1014

Cite this

@article{c38fa9e54954468e8e786000d43356b4,

title = "BRAK and APRIL as novel biomarkers for ovarian tumors",

abstract = "Aims: To evaluate BRAK and APRIL in serum samples from healthy patients and an ovarian tumor group and analyze their effective value as biomarkers. Materials and methods: BRAK and APRIL were measured in 197 serum samples including 34 healthy controls, 48 patients with benign ovarian cysts and 115 patients with ovarian cancer, and the best statistical cut-off values were calculated. Then, the sensitivity, specificity, accuracy, positive predictive value and negative predictive value for selected cut-off points were assessed. Results: The healthy control group had statistically significant higher BRAK and lower APRIL than the ovarian tumor group. BRAK was excellent for differentiating healthy patients from patients with ovarian tumors, showing area under the receiver operating characteristic curve 0.983, 98.16% sensitivity and 100% specificity. When BRAK was combined with APRIL and CA-125, it also played a role in distinguishing benign cysts from malignancies with area under the curve 0.864, 81.74% sensitivity and 79.17% specificity. Conclusions: BRAK and APRIL are good candidates for ovarian tumor biomarkers.",

author = "Heeyon Kim and Won, {Bo Hee} and Choi, {Jae Il} and Inha Lee and Lee, {Jae Hoon} and Park, {Joo Hyun} and Choi, {Young Sik} and Kim, {Jae Hoon} and Cho, {Si Hyun} and Lim, {Jong Baeck} and Lee, {Byung Seok}",

note = "Funding Information: This research was supported by a grant from the Korea Health Technology RandD Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant number HI18C2047) and supported by the National Research Foundation of Korea grant funded by the Korea government (2017R1A2B2011728). Funding Information: This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI18C2047) and supported by the National Research Foundation of Korea grant funded by the Korea government (2017R1A2B2011728). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Funding Information: Human serums were provided by the Korea Gynecologic Cancer Bank through the Bio & Medical Technology Development Program of the Ministry of Education, Science and Technology, Korea (NRF-2017M3A9B8069610). Publisher Copyright: {\textcopyright} 2022 Future Medicine Ltd.",

year = "2022",

month = jun,

doi = "10.2217/bmm-2021-1014",

language = "English",

volume = "16",

pages = "717--729",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Future Medicine Ltd.",

number = "9",

}

TY - JOUR

T1 - BRAK and APRIL as novel biomarkers for ovarian tumors

AU - Kim, Heeyon

AU - Won, Bo Hee

AU - Choi, Jae Il

AU - Lee, Inha

AU - Lee, Jae Hoon

AU - Park, Joo Hyun

AU - Choi, Young Sik

AU - Kim, Jae Hoon

AU - Cho, Si Hyun

AU - Lim, Jong Baeck

AU - Lee, Byung Seok

N1 - Funding Information: This research was supported by a grant from the Korea Health Technology RandD Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant number HI18C2047) and supported by the National Research Foundation of Korea grant funded by the Korea government (2017R1A2B2011728). Funding Information: This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI18C2047) and supported by the National Research Foundation of Korea grant funded by the Korea government (2017R1A2B2011728). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Funding Information: Human serums were provided by the Korea Gynecologic Cancer Bank through the Bio & Medical Technology Development Program of the Ministry of Education, Science and Technology, Korea (NRF-2017M3A9B8069610). Publisher Copyright: © 2022 Future Medicine Ltd.

PY - 2022/6

Y1 - 2022/6

N2 - Aims: To evaluate BRAK and APRIL in serum samples from healthy patients and an ovarian tumor group and analyze their effective value as biomarkers. Materials and methods: BRAK and APRIL were measured in 197 serum samples including 34 healthy controls, 48 patients with benign ovarian cysts and 115 patients with ovarian cancer, and the best statistical cut-off values were calculated. Then, the sensitivity, specificity, accuracy, positive predictive value and negative predictive value for selected cut-off points were assessed. Results: The healthy control group had statistically significant higher BRAK and lower APRIL than the ovarian tumor group. BRAK was excellent for differentiating healthy patients from patients with ovarian tumors, showing area under the receiver operating characteristic curve 0.983, 98.16% sensitivity and 100% specificity. When BRAK was combined with APRIL and CA-125, it also played a role in distinguishing benign cysts from malignancies with area under the curve 0.864, 81.74% sensitivity and 79.17% specificity. Conclusions: BRAK and APRIL are good candidates for ovarian tumor biomarkers.

AB - Aims: To evaluate BRAK and APRIL in serum samples from healthy patients and an ovarian tumor group and analyze their effective value as biomarkers. Materials and methods: BRAK and APRIL were measured in 197 serum samples including 34 healthy controls, 48 patients with benign ovarian cysts and 115 patients with ovarian cancer, and the best statistical cut-off values were calculated. Then, the sensitivity, specificity, accuracy, positive predictive value and negative predictive value for selected cut-off points were assessed. Results: The healthy control group had statistically significant higher BRAK and lower APRIL than the ovarian tumor group. BRAK was excellent for differentiating healthy patients from patients with ovarian tumors, showing area under the receiver operating characteristic curve 0.983, 98.16% sensitivity and 100% specificity. When BRAK was combined with APRIL and CA-125, it also played a role in distinguishing benign cysts from malignancies with area under the curve 0.864, 81.74% sensitivity and 79.17% specificity. Conclusions: BRAK and APRIL are good candidates for ovarian tumor biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85131903893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131903893&partnerID=8YFLogxK

U2 - 10.2217/bmm-2021-1014

DO - 10.2217/bmm-2021-1014

M3 - Article

C2 - 35588310

AN - SCOPUS:85131903893

SN - 1752-0363

VL - 16

SP - 717

EP - 729

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 9

ER -

BRAK and APRIL as novel biomarkers for ovarian tumors

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this